4.5 Review

The role of matrix metalloproteinases in infectious corneal ulcers

Journal

SURVEY OF OPHTHALMOLOGY
Volume 68, Issue 5, Pages 929-939

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.survophthal.2023.06.007

Keywords

Corneal ulcer; Keratitis; Metalloproteinases; Collagenases; Keratitis treatment

Categories

Ask authors/readers for more resources

During infectious keratitis, the overexpression of MMPs, particularly MMP-2 and MMP-9, leads to the degradation of corneal collagen and can cause complications. Nonspecific treatments like tetracyclines and corticosteroids are used as adjuvants to antimicrobials to alleviate corneal degradation and inflammation. Specific MMP inhibitors, pro-MMP activator inhibitors, and anti-cytokine agents have also been reported. Further studies are needed to investigate the potential of these treatments in managing infectious keratitis.
During infectious keratitis, the production of collagenolytic and inflammatory substances, along with increased corneal matrix metalloproteinase (MMP) activity, induces the degradation of corneal collagen and may cause postkeratitis complications, such as opacity, thinning, and corneal perforation. MMPs, especially MMP-2 and MMP-9, are overexpressed in infectious keratitis and sustained over time by inflammatory and nonmicrobial mechanisms. The high MMP levels are correlated with excessive corneal destruction in bacterial, herpetic, fungal, and acanthamoeba infections. Nonspecific treatments, such as tetracyclines, particularly doxycycline, or corticosteroids, are used as adjuvants to antimicrobials to alleviate the disproportionate degradation and inflammation of the corneal layers caused by corneal MMPs and decrease the recruitment and infiltration of inflammatory cells. Treatments showing inhibition of specific MMPs (Galardin, ZHAWOC7726), interfering with pro-MMP activation (EDTA, ascorbic acid), or showing anticytokine effect (epigallocatechin-2-gallate, TRAM-34) have been reported. Other treatments show a direct action over corneal collagen structure such as corneal cross-linking or have been associated with reduction of MMP levels such as amniotic membrane grafting. Although the use of these drugs has been shown in studies to be effective in controlling inflammation, especially in experimental ones, robust studies are still needed based on randomized and randomized clinical trials to demonstrate their potential effect as adjuvants in the management of infectious keratitis.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available